Atacama Labs Enters Into Partnership With Excella Gmbh
ATACAMA LABS OY and a German Based EXCELLA GmbH (Fareva Holding SA) have sgned a contract manufacturing agreement to jointly market and sell PDG Granule and Tablet Manufacturing Services for the pharmaceutical industry
Atacama Labs Oy has developed an innovative oral drug delivery technology (called 'pneumatic dry granulation' or 'PDG Technology(TM)'). The technology is aimed to replace existing solid dosage form development and manufacturing methods (like wet granulation or standard roller compaction) and will help both NCE galenic developers and life cycle managers to overcome development or differentiation issues.
The Excella / Atacama Labs partnership offers a cGMP compliant and FDA /EMEA / Anvisa certified environment to house Atacama's innovative and fully automated PDG equipment.
"We can develop almost any API (including difficult ones) into higher drug load tablets with good hardness and dissolution profiles and our clients can profit from new tablet characteristics to extend the life cycle of expiring drugs, which can mean several more years of protected sales of a blockbuster drug. In both cases, global economics can be hundreds of millions of additional revenue, naturally subject to magnitude of drug revenue," Mr. Mittwich, CEO of the Atacama Labs Oy concludes.